PPAR γ agonists in adaptive immunity: What do immune disorders and their models have to tell us?

PPAR Research

Volumn , Issue , 2013, Pages

  Da Rocha Junior, Laurindo Ferreira ^a   Dantas, Andréa Tavares ^a   Duarte, Ângela Luzia Branco Pinto ^a   De Melo Rego, Moacyr Jesus Barreto ^a   Pitta, Ivan Da Rocha ^a   Pitta, Maira Galdino Da Rocha ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; CELL NUCLEUS RECEPTOR; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17F; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 25; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; STAT1 PROTEIN; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL SURVIVAL; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DENDRITIC CELL; EFFECTOR CELL; ENTERITIS; HOST RESISTANCE; HUMAN; LIPID METABOLISM; LYMPHOCYTE DIFFERENTIATION; MESENTERY LYMPH NODE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL;

EID: 84883185883     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2013/519724     Document Type: Review

References (95)

1. Gor D. O., Rose N. R., Greenspan N. S., TH1-TH2: a procrustean paradigm. Nature Immunology 2003 4 6 503 505 2-s2.0-0038276049 10.1038/ni0603-503
2. Harrington L. E., Hatton R. D., Mangan P. R., Turner H., Murphy T. L., Murphy K. M., Weaver C. T., Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunology 2005 6 11 1123 1132 2-s2.0-27544490377 10.1038/ni1254
3. Scherer H. U., Burmester G., Adaptive immunity in rheumatic diseases-bystander or pathogenic player? Best Practice and Research 2011 25 6 785 800 2-s2.0-84855983883 10.1016/j.berh.2011.11.005
4. Burris T. P., Busby S. A., Griffin P. R., Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity. Chemistry and Biology 2012 19 1 51 59 2-s2.0-84856397813 10.1016/j.chembiol.2011.12.011
5. Szanto A., Nagy L., The many faces of PPAR γ: anti-inflammatory by any means? Immunobiology 2008 213 9-10 789 803 2-s2.0-52749088120 10.1016/j.imbio.2008.07.015
6. Clark R. B., Bishop-Bailey D., Estrada-Hernandez T., Hla T., Puddington L., Padula S. J., The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. Journal of Immunology 2000 164 3 1364 1371
7. Chung S. W., Kang B. Y., Kim T. S., Inhibition of Interleukin-4 Production in CD4+ T Cells by Peroxisome Proliferator-Activated Receptor- γ (PPAR- γ) Ligands: involvement of Physical Association between PPAR- γ and the Nuclear Factor of Activated T Cells Transcription Factor. Molecular Pharmacology 2003 64 5 1169 1179 2-s2.0-0142210174 10.1124/mol.64.5.1169
8. Schmidt M. V., Brüne B., Von Knethen A., The nuclear hormone receptor PPAR γ as a therapeutic target in major diseases. TheScientificWorldJournal 2010 10 2181 2197 2-s2.0-78650286735 10.1100/tsw.2010.213
9. Cariou B., Charbonnel B., Staels B., Thiazolidinediones and PPAR γ agonists: time for a reassessment. Trends in Endocrinology and Metabolism 2012 23 5 205 215 2-s2.0-84860375795 10.1016/j.tem.2012.03.001
10. Choi J., Bothwell A. L. M., The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases. Molecules and Cells 2012 33 3 217 222 2-s2.0-84857492034 10.1007/s10059-012-2297-y
11. Harris S. G., Phipps R. P., The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis. European Journal of Immunology 2001 31 4 1098 1105
12. Garcia-Bates T. M., Baglole C. J., Bernard M. P., Murant T. I., Simpson-Haidaris P. J., Phipps R. P., Peroxisome proliferator-activated receptor γ ligands enhance human B cell antibody production and differentiation. Journal of Immunology 2009 183 11 6903 6912 2-s2.0-73349104435 10.4049/jimmunol.0900324
13. Bowen H., Kelly A., Lee T., Lavender P., Control of cytokine gene transcription in Th1 and Th2 cells. Clinical and Experimental Allergy 2008 38 9 1422 1431 2-s2.0-50249131954 10.1111/j.1365-2222.2008.03067.x
14. Cope A., Le Friec G., Cardone J., Kemper C., The Th1 life cycle: molecular control of IFN- γ to IL-10 switching. Trends in Immunology 2011 32 6 278 286 2-s2.0-79957713226 10.1016/j.it.2011.03.010
15. Cunard R., Ricote M., DiCampli D., Archer D. C., Kahn D. A., Glass C. K., Kelly C. J., Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. Journal of Immunology 2002 168 6 2795 2802 2-s2.0-0037087324
16. Setoguchi K., Misaki Y., Terauchi Y., Yamauchi T., Kawahata K., Kadowaki T., Yamamoto K., Peroxisome proliferator-activated receptor- γ haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. Journal of Clinical Investigation 2001 108 11 1667 1675 2-s2.0-0035210586 10.1172/JCI200113202
17. Alleva D. G., Johnson E. B., Lio F. M., Boehme S. A., Conlon P. J., Crowe P. D., Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor- γ: counter-regulatory activity by IFN- γ Journal of Leukocyte Biology 2002 71 4 677 685 2-s2.0-0036554139
18. Hasegawa H., Takano H., Zou Y., Qin Y., Hizukuri K., Odaka K., Toyozaki T., Komuro I., Pioglitazone, a peroxisome proliferator-activated receptor γ activator, ameliorates experimental autoimmune myocarditis by modulating Th1/Th2 balance. Journal of Molecular and Cellular Cardiology 2005 38 2 257 265 2-s2.0-13444274720 10.1016/j.yjmcc.2004.11.010
19. Feinstein D. L., Galea E., Gavrilyuk V., Brosnan C. F., Whitacre C. C., Dumitrescu-Ozimek L., Landreth G. E., Pershadsingh H. A., Weinberg G., Heneka M. T., Peroxisome proliferator-activated receptor- γ agonists prevent experimental autoimmune encephalomyelitis. Annals of Neurology 2002 51 6 694 702 2-s2.0-0036260784 10.1002/ana.10206
20. Tomita T., Kakiuchi Y., Tsao P. S., THR0921, a novel peroxisome proliferator-activated receptor gamma agonist, reduces the severity of collagen-induced arthritis. Arthritis Research & Therapy 2006 8 1 R7 2-s2.0-33746705095
21. Reilly C. M., Oates J. C., Cook J. A., Morrow J. D., Halushka P. V., Gilkeson G. S., Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor- γ agonists. Journal of Immunology 2000 164 3 1498 1504 2-s2.0-0034141531
22. Awara W. M., El-Sisi A. E., El-Refaei M., El-Naa M. M., El-Desoky K., Insulinotropic and anti-inflammatory effects of rosiglitazone in experimental autoimmune diabetes. The Review of Diabetic Studies 2005 2 3 146 156
23. Yang X. Y., Wang L. H., Chen T., Hodge D. R., Resau J. H., DaSilva L., Farrar W. L., Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor γ (PPAR γ) agonists. PPAR γ co-association with transcription factor NFAT. Journal of Biological Chemistry 2000 275 7 4541 4544 2-s2.0-0001297403 10.1074/jbc.275.7.4541
24. Marx N., Kehrle B., Kohlhammer K., Grüb M., Koenig W., Hombach V., Libby P., Plutzky J., PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circulation Research 2002 90 6 703 710 2-s2.0-0037023635 10.1161/01.RES.0000014225.20727.8F
25. Yang X. Y., Wang L. H., Mihalic K., Xiao W., Chen T., Li P., Wahl L. M., Farrar W. L., Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated receptor γ activated by macrophage-derived 12/15-lipoxygenase ligands. Journal of Biological Chemistry 2002 277 6 3973 3978 2-s2.0-0037040293 10.1074/jbc.M105619200
26. Okosieme O. E., Parkes A. B., Premawardhana L. D. K. E., Thomas A. W., Evans L. M., Lazarus J. H., Peripheral cytokine expression in autoimmune thyroiditis: effects of in vitro modulation by rosiglitazone and dexamethasone. Thyroid 2006 16 10 953 960 2-s2.0-33846451817 10.1089/thy.2006.16.953
27. Antonelli A., Ferrari S. M., Fallahi P., Ghiri E., Crescioli C., Romagnani P., Vitti P., Serio M., Ferrannini E., Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists. Cytokine 2010 50 3 260 267 2-s2.0-77952534161 10.1016/j.cyto.2010.01.009
28. Antonelli A., Rotondi M., Ferrari S. M., Fallahi P., Romagnani P., Franceschini S. S., Serio M., Ferrannini E., Interferon- γ -inducible α -chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor- γ agonists. Journal of Clinical Endocrinology and Metabolism 2006 91 2 614 620 2-s2.0-32544456285 10.1210/jc.2005-1689
29. Augstein P., Dunger A., Heinke P., Wachlin G., Berg S., Hehmke B., Salzsieder E., Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN- γ expression in splenic T cells. Biochemical and Biophysical Research Communications 2003 304 2 378 384 2-s2.0-0344088433 10.1016/S0006-291X(03) 00590-4
30. Giorgini A. E., Beales P. E., Mire-Sluis A., Scott D., Liddi R., Pozzilli P., Troglitazone exhibits immunomodulatory activity on the cytokine production of activated human lymphocytes. Hormone and Metabolic Research 1999 31 1 1 4 2-s2.0-0032994819
31. Hontecillas R., Bassaganya-Riera J., Peroxisome proliferator-activated receptor γ is required for regulatory CD4+ T cell-mediated protection against colitis. Journal of Immunology 2007 178 5 2940 2949 2-s2.0-33847403883
32. Diab A., Deng C., Smith J. D., Hussain R. Z., Phanavanh B., Lovett-Racke A. E., Drew P. D., Racke M. K., Peroxisome proliferator-activated receptor- γ agonist 15-deoxy-Δ12,14-prostaglandin J2 ameliorates experimental autoimmune encephalomyelitis. Journal of Immunology 2002 168 5 2508 2515 2-s2.0-0036499074
33. Diab A., Hussain R. Z., Lovett-Racke A. E., Chavis J. A., Drew P. D., Racke M. K., Ligands for the peroxisome proliferator-activated receptor- γ and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 2004 148 1-2 116 126 2-s2.0-1242317642 10.1016/j.jneuroim.2003.11.010
34. Marx N., Mach F., Sauty A., Leung J. H., Sarafi M. N., Ransohoff R. M., Libby P., Plutzky J., Luster A. D., Peroxisome proliferator-activated receptor- γ activators inhibit IFN- γ-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. Journal of Immunology 2000 164 12 6503 6508 2-s2.0-0034660182
35. Housley W. J., Adams C. O., Vang A. G., Brocke S., Nichols F. C., LaCombe M., Rajan T. V., Clark R. B., Peroxisome proliferator-activated receptor γ is required for CD4 + T cell-mediated lymphopenia-associated autoimmunity. Journal of Immunology 2011 187 8 4161 4169 2-s2.0-80054747182 10.4049/jimmunol.1101731
36. Leonard J. P., Waldburger K. E., Goldman S. J., Murray H. W., Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. Journal of Experimental Medicine 1995 181 1 381 386 2-s2.0-0028966091 10.1084/jem.181.1.381
37. Leonard J. P., Waldburger K. E., Schaub R. G., Smith T., Hewson A. K., Cuzner M. L., Goldman S. J., Regulation of the inflammatory response in animal models of multiple sclerosis by interleukin-12. Critical Reviews in Immunology 1997 17 5-6 545 553 2-s2.0-0030692778
38. Natarajan C., Bright J. J., Peroxisome proliferator-activated receptor-gamma agonist inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes and Immunity 2002 3 2 59 70 2-s2.0-0036546185 10.1038/sj.gene.6363832
39. Drew P. D., Chavis J. A., The cyclopentone prostaglandin 15-deoxy-Δ12,14 prostaglandin J2 represses nitric oxide, TNF- α and IL-12 production by microglial cells. Journal of Neuroimmunology 2001 115 1-2 28 35 2-s2.0-0035795009 10.1016/S0165-5728(01)00267-3
40. Chung S. W., Kang B. Y., Kim K., Pak Y. K., Cho D., Trinchieri G., Tae Sung Kim T. S. K., Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor- γ and nuclear factor- B. Journal of Biological Chemistry 2000 275 42 32681 32687 2-s2.0-0034693323
41. Zhu J., Paul W. E., CD4 T cells: fates, functions, and faults. Blood 2008 112 5 1557 1569 2-s2.0-52649167708 10.1182/blood-2008-05-078154
42. Singh R. R., IL-4 and many roads to lupuslike autoimmunity. Clinical Immunology 2003 108 2 73 79 2-s2.0-0042062277 10.1016/S1521-6616(03)00145-1
43. Apostolidis S. A., Lieberman L. A., Kis-Toth K., Crispín J. C., Tsokos G. C., The dysregulation of cytokine networks in systemic lupus erythematosus. Journal of Interferon and Cytokine Research 2011 31 10 769 779 2-s2.0-80054684397 10.1089/jir.2011.0029
44. Tran G. T., Hodgkinson S. J., Carter N. M., IL-5 promotes induction of antigen-specific CD4+CD25+ T regulatory cells that suppress autoimmunity. Blood 2012 119 19 4441 4450 10.1182/blood-2011-12-396101
45. Chtanova T., Kemp R. A., Sutherland A. P. R., Ronchese F., Mackay C. R., Gene microarrays reveal extensive differential gene expression in both CD4+ and CD8+ type 1 and type 2 T cells. Journal of Immunology 2001 167 6 3057 3063 2-s2.0-0035884779
46. Saubermann L. J., Nakajima A., Wada K., Zhao S., Terauchi Y., Kadowaki T., Aburatani H., Matsuhashi N., Nagai R., Blumberg R. S., Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflammatory Bowel Diseases 2002 8 5 330 339 2-s2.0-0036743165
47. Celinski K., Dworzanski T., Fornal R., Korolczuk A., Madro A., Slomka M., Comparison of the anti-inflammatory and therapeutic actions of PPAR-gamma agonists rosiglitazone and troglitazone in experimental colitis. Journal of Physiology and Pharmacology 2012 63 6 631 640
48. Ramkalawan H., Wang Y. Z., Hurbungs A., Pioglitazone, PPAR γ agonist, attenuates experimental autoimmune neuritis. Inflammation 2012 35 4 1338 1347
49. Rühl R., Dahten A., Schweigert F. J., Herz U., Worm M., Inhibition of IgE-production by peroxisome proliferator-activated receptor ligands. Journal of Investigative Dermatology 2003 121 4 757 764 10.1046/j.1523-1747.2003.12493. x
50. Kim S. R., Kyung S. L., Hee S. P., Seoung J. P., Kyung H. M., Sun M. J., Yong C. L., Involvement of IL-10 in peroxisome proliferator-activated receptor γ -mediated anti-inflammatory response in asthma. Molecular Pharmacology 2005 68 6 1568 1575 2-s2.0-27844504748 10.1124/mol.105.017160
51. Won H. Y., Min H. J., Ahn J. H., Yoo S., Bae M. A., Hong J., Hwang E. S., Anti-allergic function and regulatory mechanisms of KR62980 in allergen-induced airway inflammation. Biochemical Pharmacology 2010 79 6 888 896 2-s2.0-74149086222 10.1016/j.bcp.2009.10.023
52. Huang J. T., Welch J. S., Ricote M., Binder C. J., Willson T. M., Kelly C., Witztum J. L., Funk C. D., Conrad D., Glass C. K., Interleukin-4-dependent production of PPAR- γ ligands in macrophages by 12/15-lipoxygenase. Nature 1999 400 6742 378 382 2-s2.0-0033595261 10.1038/22572
53. Ricote M., Welch J. S., Glass C. K., Regulation of macrophage gene expression by the peroxisome proliferator-activated receptor- γ Hormone Research 2000 54 5-6 275 280 2-s2.0-0034583170 10.1159/000053271
54. Dahten A., Mergemeier S., Worm M., PPAR γ expression profile and its cytokine driven regulation in atopic dermatitis. Allergy 2007 62 8 926 933 2-s2.0-34447131528 10.1111/j.1398-9995.2007.01444.x
55. Wang A. C., Dai X., Luu B., Conrad D. J., Peroxisome proliferator- activated receptor- γ regulates airway epithelial cell activation. American Journal of Respiratory Cell and Molecular Biology 2001 24 6 688 693 2-s2.0-0034973231
56. Del Prete G., De Carli M., Almerigogna F., Giudizi M. G., Biagiotti R., Romagnani S., Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. Journal of Immunology 1993 150 2 353 360 2-s2.0-0027204621
57. Davis L. S., Hutcheson J., Mohan C., The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus. Journal of Interferon and Cytokine Research 2011 31 10 781 789 2-s2.0-80054709328 10.1089/jir.2011.0047
58. Thompson P. W., Bayliffe A. I., Warren A. P., Lamb J. R., Interleukin-10 is upregulated by nanomolar rosiglitazone treatment of mature dendritic cells and human CD4+ T cells. Cytokine 2007 39 3 184 191 2-s2.0-35348990389 10.1016/j.cyto.2007.07.191
59. Ji J. D., Kim H. J., Rho Y. H., Choi S. J., Lee Y. H., Cheon H. J., Sohn J., Song G. G., Inhibition of IL-10-induced STAT3 activation by 15-deoxy-Δ12,14-prostaglandin J2. Rheumatology 2005 44 8 983 988 2-s2.0-24944554988 10.1093/rheumatology/keh657
60. Komai-Koma M., Xu D., Li Y., McKenzie A. N. J., McInnes I. B., Liew F. Y., IL-33 is a chemoattractant for human Th2 cells. European Journal of Immunology 2007 37 10 2779 2786 2-s2.0-35348850153 10.1002/eji.200737547
61. Kurowska-Stolarska M., Kewin P., Murphy G., Russo R. C., Stolarski B., Garcia C. C., Komai-Koma M., Pitman N., Li Y., McKenzie A. N. J., Teixeira M. M., Liew F. Y., Xu D., IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. Journal of Immunology 2008 181 7 4780 4790 2-s2.0-58149300244
62. Farnesi-de-Assunção T. S., Alves C. F., Carregaro V., de Oliveira J. R., da Silva C. A. T., Cheraim A. B., Cunha F. Q., Napimoga M. H., PPAR- γ agonists, mainly 15d-PGJ2, reduce eosinophil recruitment following allergen challenge. Cellular Immunology 2012 273 1 23 29 2-s2.0-84856013535 10.1016/j.cellimm.2011.11.010
63. Bettelli E., Korn T., Oukka M., Kuchroo V. K., Induction and effector functions of TH17 cells. Nature 2008 453 7198 1051 1057 2-s2.0-45749101727 10.1038/nature07036
64. Cua D. J., Sherlock J., Chen Y., Murphy C. A., Joyce B., Seymour B., Lucian L., To W., Kwan S., Churakova T., Zurawski S., Wiekowski M., Lira S. A., Gorman D., Kastelein R. A., Sedgwick J. D., Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003 421 6924 744 748 2-s2.0-0037434789 10.1038/nature01355
65. Murphy C. A., Langrish C. L., Chen Y., Blumenschein W., McClanahan T., Kastelein R. A., Sedgwick J. D., Cua D. J., Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation. Journal of Experimental Medicine 2003 198 12 1951 1957 2-s2.0-0346962972 10.1084/jem.20030896
66. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., Mckenzie B., Kleinschek M. A., Owyang A., Mattson J., Blumenschein W., Murphy E., Sathe M., Cua D. J., Kastelein R. A., Rennick D., IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. Journal of Clinical Investigation 2006 116 5 1310 1316 2-s2.0-33646397611 10.1172/JCI21404
67. Klotz L., Knolle P., Nuclear receptors: TH17 cell control from within. FEBS Letters 2011 585 23 3764 3769 2-s2.0-81755179403 10.1016/j.febslet.2011.06. 027
68. Hwang E. S., Transcriptional regulation of T helper 17 cell differentiation. Yonsei Medical Journal 2010 51 4 484 491 2-s2.0-77956215618 10.3349/ymj.2010.51.4.484
69. Klotz L., Burgdorf S., Dani I., Saijo K., Flossdorf J., Hucke S., Alferink J., Novak N., Beyer M., Mayer G., Langhans B., Klockgether T., Waisman A., Eberl G., Schultze J., Famulok M., Kolanus W., Glass C., Kurts C., Knolle P. A., The nuclear receptor PPAR γ selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. Journal of Experimental Medicine 2009 206 10 2079 2089 2-s2.0-70350459594 10.1084/jem.20082771
70. Mus A. M., Cornelissen F., Asmawidjaja P. S., Van Hamburg J. P., Boon L., Hendriks R. W., Lubberts E., Interleukin-23 promotes Th17 differentiation by inhibiting T-bet and FoxP3 and is required for elevation of Interleukin-22, but not Interleukin-21, in autoimmune experimental arthritis. Arthritis and Rheumatism 2010 62 4 1043 1050 2-s2.0-77950548359 10.1002/art.27336
71. Haines C. J., Chen Y., Blumenschein W., Autoimmune memory T helper 17 cell function and expansion are dependent on interleukin-23. Cell Reports 2013 3 5 1378 1388 10.1016/j.celrep.2013.03.035
72. Xu J., Drew P. D., Peroxisome proliferator-activated receptor- γ agonists suppress the production of IL-12 family cytokines by activated glia. Journal of Immunology 2007 178 3 1904 1913 2-s2.0-33846468972
73. Park S. J., Lee K. S., Kim S. R., Min K. H., Choe Y. H., Moon H., Chae H. J., Yoo W. H., Lee Y. C., Peroxisome proliferator-activated receptor γ agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation. Journal of Immunology 2009 183 5 3259 3267 2-s2.0-70349249624 10.4049/jimmunol.0900231
74. Wing K., Sakaguchi S., Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nature Immunology 2010 11 1 7 13 2-s2.0-74049164847 10.1038/ni.1818
75. Adachi M., Kurotani R., Morimura K., Shah Y., Sanford M., Madison B. B., Gumucio D. L., Marin H. E., Peters J. M., Young H. A., Gonzalez F. J., Peroxisome proliferator activated receptor γ in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 2006 55 8 1104 1113 2-s2.0-33746159991 10.1136/gut.2005.081745
76. Shah Y. M., Morimura K., Gonzalez F. J., Expression of peroxisome proliferator-activated receptor- γ in macrophage suppresses experimentally induced colitis. American Journal of Physiology 2007 292 2 G657 G666 2-s2.0-33847039159 10.1152/ajpgi.00381.2006
77. Hori S., Nomura T., Sakaguchi S., Control of regulatory T cell development by the transcription factor Foxp3. Science 2003 299 5609 1057 1061 2-s2.0-0347785480 10.1126/science.1079490
78. Guri A. J., Mohapatra S. K., Horne W. T. II, Hontecillas R., Bassaganya-Riera J., The Role of T cell PPAR γ in mice with experimental inflammatory bowel disease. BMC Gastroenterology 2010 10 60 2-s2.0-77953248869 10.1186/1471-230X-10-60
79. Baratelli F., Lin Y., Zhu L., Yang S., Heuzé-Vourc'h N., Zeng G., Reckamp K., Dohadwala M., Sharma S., Dubinett S. M., Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. Journal of Immunology 2005 175 3 1483 1490 2-s2.0-22544436066
80. Wohlfert E. A., Nichols F. C., Nevius E., Clark R. B., Peroxisome proliferator-activated receptor γ (PPAR γ) and immunoregulation: enhancement of regulatory T cells through PPAR γ-dependent and -independent mechanisms. Journal of Immunology 2007 178 7 4129 4135 2-s2.0-33947615887
81. Feuerer M., Herrero L., Cipolletta D., Naaz A., Wong J., Nayer A., Lee J., Goldfine A. B., Benoist C., Shoelson S., Mathis D., Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nature Medicine 2009 15 8 930 939 2-s2.0-68349148211 10.1038/nm.2002
82. Cipolletta D., Feuerer M., Li A., PPAR- γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 2012 486 7404 549 553
83. Hamaguchi M., Sakaguchi S., Regulatory T cells expressing PPAR- γ control inflammation in obesity. Cell Metabolism 2012 16 1 4 6 10.1016/j.cmet.2012.06.007
84. Edwards J. C. W., Szczepański L., Szechiński J., Filipowicz-Sosnowska A., Emery P., Close D. R., Stevens R. M., Shaw T., Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New England Journal of Medicine 2004 350 25 2572 2581 2-s2.0-2942537697 10.1056/NEJMoa032534
85. Isenberg D. A., Treating patients with lupus with B-cell depletion. Lupus 2008 17 5 400 404 2-s2.0-44849121063 10.1177/0961203308090024
86. Stone J. H., Rituximab versus cyclophosphamide for ANCA-associated vasculitis. The New England Journal of Medicine 2010 363 3 221 232 2-s2.0-78649439569
87. Hawker K., O'Connor P., Freedman M. S., Calabresi P. A., Antel J., Simon J., Hauser S., Waubant E., Vollmer T., Panitch H., Zhang J., Chin P., Smith C. H., Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology 2009 66 4 460 471 2-s2.0-70449418132 10.1002/ana.21867
88. McQueen F., A B cell explanation for autoimmune disease: the forbidden clone returns. Postgraduate Medical Journal 2012 88 1038 226 233 2-s2.0-84859101709 10.1136/postgradmedj-2011-130364
89. Padilla J., Kaur K., Cao H. J., Smith T. J., Phipps R. P., Peroxisome proliferator activator receptor- γ agonists and 15-deoxy-Δ12,14-PGJ2 induce apoptosis in normal and malignant B-lineage cells. Journal of Immunology 2000 165 12 6941 6948 2-s2.0-0034672055
90. Padilla J., Leung E., Phipps R. P., Human B lymphocytes and B lymphomas express PPAR- γ and are killed by PPAR- γ agonists. Clinical Immunology 2002 103 1 22 33 2-s2.0-0036245961 10.1006/clim.2001.5181
91. Oxer D. S., Godoy L. C., Borba E., Lima-Salgado T., Passos L. A., Laurindo I., Kubo S., Barbeiro D. F., Fernandes D., Laurindo F. R., Velasco I. T., Curi R., Bonfa E., Souza H. P., PPAR γ expression is increased in systemic lupus erythematosus patients and represses CD40/CD40L signaling pathway. Lupus 2011 20 6 575 587 2-s2.0-79956122674 10.1177/0961203310392419
92. Aprahamian T., Bonegio R. G., Richez C., Yasuda K., Chiang L., Sato K., Walsh K., Rifkin I. R., The peroxisome proliferator-activated receptor γ agonist rosiglitazone ameliorates murine lupus by induction of adiponectin. Journal of Immunology 2009 182 1 340 346 2-s2.0-59849087383
93. Vogel L. A., Showe L. C., Lester T. L., McNutt R. M., Van Cleave V. H., Metzger D. W., Direct binding of IL-12 to human and murine B lymphocytes. Int Immunol 1996 8 12 1955 1962 10.1093/intimm/8.12.1955
94. Dubois B., Massacrier C., Vanbervliet B., Fayette J., Brière F., Banchereau J., Caux C., Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes. Journal of Immunology 1998 161 5 2223 2231 2-s2.0-0032167549
95. Estes D. M., Tuo W., Brown W. C., Goin J., Effects of type I/type II interferons and transforming growth factor- β on B-cell differentiation and proliferation. Definition of costimulation and cytokine requirements for immunoglobulin synthesis and expression. Immunology 1998 95 4 604 611 2-s2.0-0031772561 10.1046/j.1365-2567.1998.00645.x